OptimizeRx Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, executive compensation, equity plan amendments, and auditor ratification. All directors were elected, executive compensation and increased equity plan shares were approved, but the evergreen provision was not. Auditor ratification passed.
-
A scalable, AI-driven point-of-care platform is expanding its reach in the pharma industry, delivering industry-leading ROI and script lift through deep EHR integration and patented technology. Growth is accelerating via DSP partnerships, with strong financials and a significant market opportunity ahead.
-
Q1 2026 saw revenue of $19.8M and adjusted EBITDA of $3.3M, with strong DAAP growth offset by macro headwinds and client-specific disruptions. 2026 revenue guidance was lowered to $95–$100M, but margin and EBITDA outlooks remain robust.
Fiscal Year 2025
-
Q4 and FY 2025 results exceeded expectations with strong revenue, margin, and cash flow growth, driven by both large and mid-tier clients. 2026 guidance is more conservative due to market shifts and cautious client spending, but profitability focus and new partnerships support long-term optimism.
-
Operational and financial momentum remains strong, with improved revenue visibility and margin expansion driven by subscription-based models and favorable product mix. Guidance is conservative, with stable operating expenses and no contribution from new partnerships like Lamar included.
-
Q2 2025 saw 55% revenue growth and a return to profitability, with gross margin and cash flow both improving. Guidance for 2025 was raised, and strong contracted revenue growth provides visibility, while accelerated debt repayment and a robust digital offering position the company well.
-
Q1 2025 revenue grew 11% year-over-year to $21.9 million, with adjusted EBITDA at $1.5 million and over 80% of full-year revenue already contracted. Guidance was raised to $101–$106 million in revenue and $13–$15 million in adjusted EBITDA, supported by strong pipeline and early subscription model momentum.
Fiscal Year 2024
-
Revenue and adjusted EBITDA exceeded expectations in 2024, driven by DAAP growth and margin expansion. Recurring revenue and customer centricity are strategic priorities, with a three- to five-year path to Rule of 40 and strong contracted revenue visibility for 2025.
-
Q3 revenue rose 30% year-over-year to $21.3M, with strong HCP growth offsetting DTC softness. Updated 2024 guidance calls for $88–$92M revenue and $8–$10M Adjusted EBITDA, as the business shifts to self-service DTC and expands DAP adoption. Four clients are expected to generate over $10M each in 2025.
-
Q2 2024 saw 36% revenue growth and improved margins, but revenue missed expectations due to a delayed $6M DAAP deal, now expected to close in Q3. Strong DAAP adoption, improved KPIs, and robust pipeline support confidence in meeting full-year guidance.